Best Hospitals for Leukemia Treatment in UAE

The total cost of leukaemia treatment varies significantly based on the specific treatment modality, number of chemotherapy cycles, disease subtype, and whether a Bone Marrow Transplant (BMT) is required. In India, at JCI- and NABH-accredited centres such as Tata Memorial Hospital (Mumbai), AIIMS (Delhi), Fortis Memorial Research Institute (Gurugram), Apollo Hospitals, or Manipal Hospitals, estimated costs are as follows: - Chemotherapy (induction + 1–2 consolidation cycles): USD 12,000 – USD 22,000 - Targeted therapy initiation and monitoring (e.g., TKI for CML, venetoclax-based regimen): USD 8,000 – USD 18,000 (excluding ongoing monthly drug costs) - Autologous BMT: USD 18,000 – USD 28,000 - Allogeneic BMT (matched sibling or unrelated donor): USD 28,000 – USD 55,000 These costs typically include hospital admission, chemotherapy drug administration, blood product support, infection prophylaxis, bone marrow biopsy, standard nursing in HEPA-filtered BMT rooms, and haematologist fees. CAR-T cell therapy, where available, carries additional manufacturing costs. In the UAE, at JCI- and DHA/MOHAP-licensed centres such as Cleveland Clinic Abu Dhabi, Burjeel Medical City, American Hospital Dubai, or Mediclinic City Hospital (Dubai), estimated costs are approximately 60–80% higher: - Chemotherapy (induction + consolidation): USD 28,000 – USD 50,000 - Targeted therapy initiation and monitoring: USD 20,000 – USD 40,000 - Autologous BMT: USD 45,000 – USD 65,000 - Allogeneic BMT: USD 65,000 – USD 110,000 The UAE premium reflects higher hospital infrastructure costs, luxury single-room accommodation, and broader multi-language concierge services. For patients from the Gulf Cooperation Council, East Africa, or Europe, the reduced travel burden may justify the higher cost. GAF Healthcare provides personalised cost estimates for each patient's specific protocol after case review, with no hidden charges.

The minimum in-country stay before safe international travel (fit-to-fly clearance) depends critically on which treatment pathway is undertaken: CHEMOTHERAPY-ONLY (Induction ± Consolidation): Patients receiving induction chemotherapy (e.g., '7+3' for AML, hyper-CVAD Cycle 1A for ALL) must remain in-country for the full induction admission (21–28 days) plus post-nadir recovery. Fit-to-fly clearance is typically issued 4–6 weeks after the completion of each cycle, once the absolute neutrophil count (ANC) has recovered to >1.0 × 10⁹/L, platelet count is >50 × 10⁹/L, there is no active infection, and the patient is clinically stable. Patients requiring multiple consolidation cycles will need to either remain in-country between cycles or return for each cycle — a factor GAF Healthcare discusses during treatment planning so the patient's schedule and visa are managed accordingly. TARGETED THERAPY (TKIs, Venetoclax, BTK Inhibitors): For patients initiated on targeted oral therapies (e.g., imatinib/dasatinib for CML, venetoclax ramp-up for AML/CLL), the initial in-country stay for dose titration, toxicity monitoring, and response assessment is typically 3–4 weeks. Fit-to-fly clearance is issued once the patient has reached their maintenance dose without significant adverse events and has been educated on drug administration, monitoring parameters, and emergency contact protocols. Ongoing therapy is continued at home with periodic telemedicine review. BONE MARROW TRANSPLANT (Allogeneic or Autologous HSCT): This is the longest pathway. Patients must plan for a minimum 90 days in-country post-transplant (Day 0). The critical early post-transplant period (Day 0 to Day +100) requires: - Weeks 1–4: Inpatient in the BMT unit for engraftment, infection monitoring, GVHD prophylaxis, and transfusion support - Weeks 5–16: Daily to twice-weekly outpatient clinic attendance (must reside within 30–60 minutes of the transplant centre) for CBC, drug levels, CMV/EBV surveillance, and GVHD assessment - Day +100 evaluation: Bone marrow assessment and chimerism analysis to determine response and further management Fit-to-fly after BMT requires: confirmed full engraftment, ANC >1.0 × 10⁹/L without G-CSF, no active acute GVHD (Grade II or above), no active systemic infection, patient fully educated on immunosuppression regimen and emergency protocols, and explicit written medical clearance from the transplant physician. In straightforward, uncomplicated allogeneic BMT with MSD, this typically occurs between Day +90 and Day +120. Complicated transplants (GVHD, infections, slow engraftment) may require 5–6 months in-country. GAF Healthcare helps families plan long-stay accommodation, attendant visas, and financial logistics for the full required duration.

Outcomes in leukaemia treatment are highly subtype-specific, risk-stratified, and influenced by disease biology, patient age, performance status, and the expertise of the treating centre. The following evidence-based benchmarks reflect outcomes achieved at high-volume, internationally accredited centres in India and the UAE that are partnered with GAF Healthcare: ACUTE MYELOID LEUKAEMIA (AML): - Complete Remission (CR) after induction chemotherapy: 60–80% of patients achieve morphological CR after one '7+3' induction cycle; a second induction achieves CR in an additional 10–15% - 5-year Overall Survival (OS) — Favourable risk (CBF-AML, NPM1-mutated without FLT3-ITD): 50–70% with chemotherapy alone - 5-year OS — Intermediate risk: 35–50%; Adverse risk (TP53, complex karyotype, FLT3-ITD high allelic ratio): 15–25% with chemotherapy alone, improved to 30–45% with allogeneic BMT in CR1 - Allogeneic BMT in CR1 (Intermediate/Adverse risk): 5-year DFS of 40–55% - Venetoclax + Azacitidine (unfit patients): CR/CRi rate 66%; Median OS 14.7 months vs. 9.6 months with azacitidine alone (VIALE-A trial) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): - Complete Remission after induction: 85–95% in adults - 5-year OS — Standard risk ALL: 50–65%; High-risk ALL: 30–50%; Ph+ ALL (with TKI + chemotherapy): 40–55% - Paediatric ALL (all risk groups): Event-Free Survival of 85–90% with modern BFM-based protocols - Blinatumomab for MRD+ ALL: MRD negativity achieved in 78% of patients; associated with improved OS vs. chemotherapy alone - Allogeneic BMT in CR2 (relapsed ALL): 5-year DFS 30–45% - CAR-T (tisagenlecleucel, paediatric/young adult R/R ALL): Overall remission rate 81%; 12-month EFS 50% in pivotal ELIANA trial CHRONIC MYELOID LEUKAEMIA (CML): - Major Molecular Response (MMR, BCR-ABL1 ≤0.1% IS) at 12 months with first-line TKI: 70–75% (imatinib), 76–80% (dasatinib/nilotinib), 82–87% (asciminib as second-line) - Treatment-Free Remission (TFR) — eligible patients after sustained deep molecular response (MR4.5): ~50% maintain remission off TKI - 10-year OS in CP-CML on TKI therapy: >85%, approaching normal life expectancy in optimal responders CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): - Progression-Free Survival (PFS) with venetoclax + obinutuzumab (CLL14 trial): 5-year PFS 62% vs. 27% with chlorambucil + obinutuzumab - Acalabrutinib-based regimens in relapsed/refractory CLL: 2-year PFS ~80% - Ibrutinib as first-line CLL (RESONATE-2): 7-year PFS 59%; OS 78% IMPORTANT CONTEXT: These success rates represent population-level data from clinical trials and registry analyses. Individual outcomes depend on accurate molecular risk stratification, MRD-guided treatment adaptation, transplant centre volume, and post-treatment monitoring compliance. GAF Healthcare's partner centres publish their own institutional transplant outcome data and are registered with national and international registries (EBMT, CIBMTR, NMDP). During your initial consultation, the treating haematologist will provide a personalised prognosis estimate based on your specific cytogenetics, molecular profile, performance status, and treatment history.